NCT02241629

Levo Phencynonate Hydrochloride for the Prevention of Seasickness

Levo Phencynonate Hydrochloridefor the Prevention of Motion Sickness (Seasickness): a Randomized, Double-blind, Placebo Controlled, Multicenter,PhaseⅡClinical Study

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 180 (actual)
• Sponsor: Sihuan Pharmaceutical Holdings Group Ltd. · Industry
• Sex: All
• Age: 18 Years – 55 Years
• Healthy volunteers: Accepted

Summary

A double-blind, randomized, placebo controlled, multicenter, dose-finding phaseⅡclinical superiority study.

Detailed description

The trial is composed by 3 parts: 1) On-boat screening period for seasickness and safety tests will be evaluated in minus one day. 2) 4 weeks of washout period to eliminate the impact of voyage experience. 3) On-boat drug testing period. The subjects will be administered the drug before voyage. The seasickness symptoms will be evaluated during voyage. The safety test will be conducted before and after one day of on-boat testing.

Conditions

• Motion Sickness

Interventions

Type	Name	Description
DRUG	placebo	placebo of levo phencynonate hydrochloride
DRUG	levo phencynonate hydrochloride	levo phencynonate hydrochloride

Timeline

• Start date: 2014-08-01
• Primary completion: 2014-12-01
• Completion: 2015-02-01
• First posted: 2014-09-16
• Last updated: 2015-05-07

Locations

1 site across 1 country: China